Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393703 | 0.82 | POLB (0.46) | ALDH1A1POLBHTTTDP1ALOX5AP | |
| SCHEMBL7034943 | 0.79 | ALOX5AP (0.45) | ALDH1A1KDM4EALOX5APKMT2ATP53 | |
| SCHEMBL5472139 | 0.77 | KDM4E (0.48) | ALDH1A1POLBHTTKDM4EKMT2A | |
| SCHEMBL4452004 | 0.75 | CMA1 (0.51) | ALDH1A1POLBKDM4EKMT2AMAPT | |
| SCHEMBL14557072 | 0.74 | TDP1 (0.55) | ALDH1A1POLBHTTTDP1MAPT | |
| SCHEMBL3279450 | 0.72 | CCR2 (0.58) | ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL10353544 | 0.70 | SMN1; SMN2 (0.69) | ALDH1A1HTTTDP1KDM4EALOX5AP | |
| SCHEMBL3146129 | 0.70 | TDP1 (0.53) | ALDH1A1POLBHTTTDP1KDM4E | |
| SCHEMBL3276758 | 0.70 | CCR2 (0.58) | ALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL1104364 | 0.69 | ALDH1A1 (0.55) | ALDH1A1POLBHTTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | ALDH1A1 687/4885POLB 2758/4885HTT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.